EGFR and neoplasm: Overall survival (OS) was evaluated using Kaplan-Meier analysis, Cox proportional hazards models adjusted for age, sex, tumor stage, smoking status, and EGFR mutation status, and restricted cubic spline analysis to examine the dose-response relationship between IAS-121 and mortality risk.